Antibody microarrays: Current status and key technological advances

Research output: Contribution to journalReview article

Standard

Antibody microarrays: Current status and key technological advances. / Wingren, Christer; Borrebaeck, Carl.

In: OMICS: A Journal of Integrative Biology, Vol. 10, No. 3, 2006, p. 411-427.

Research output: Contribution to journalReview article

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Antibody microarrays: Current status and key technological advances

AU - Wingren, Christer

AU - Borrebaeck, Carl

PY - 2006

Y1 - 2006

N2 - Antibody-based microarrays are among the novel classes of rapidly evolving proteomic technologies that holds great promise in biomedicine. Miniaturized microarrays (< 1 cm(2)) can be printed with thousands of individual antibodies carrying the desired specificities, and with biological sample (e.g., an entire proteome) added, virtually any specifically bound analytes can be detected. While consuming only minute amounts (<mu L scale) of reagents, ultra-sensitive assays (zeptomol range) can readily be performed in a highly multiplexed manner. The microarray patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, revealing the composition of the proteome. Thus, protein expression profiling and global proteome analysis using this tool will offer new opportunities for drug target and biomarker discovery, disease diagnostics, and insights into disease biology. Adopting the antibody microarray technology platform, several biomedical applications, ranging from focused assays to proteome-scale analysis will be rapidly emerging in the coming years. This review will discuss the current status of the antibody microarray technology focusing on recent technological advances and key issues in the process of evolving the methodology into a high-performing proteomic research tool.

AB - Antibody-based microarrays are among the novel classes of rapidly evolving proteomic technologies that holds great promise in biomedicine. Miniaturized microarrays (< 1 cm(2)) can be printed with thousands of individual antibodies carrying the desired specificities, and with biological sample (e.g., an entire proteome) added, virtually any specifically bound analytes can be detected. While consuming only minute amounts (<mu L scale) of reagents, ultra-sensitive assays (zeptomol range) can readily be performed in a highly multiplexed manner. The microarray patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, revealing the composition of the proteome. Thus, protein expression profiling and global proteome analysis using this tool will offer new opportunities for drug target and biomarker discovery, disease diagnostics, and insights into disease biology. Adopting the antibody microarray technology platform, several biomedical applications, ranging from focused assays to proteome-scale analysis will be rapidly emerging in the coming years. This review will discuss the current status of the antibody microarray technology focusing on recent technological advances and key issues in the process of evolving the methodology into a high-performing proteomic research tool.

U2 - 10.1089/omi.2006.10.411

DO - 10.1089/omi.2006.10.411

M3 - Review article

VL - 10

SP - 411

EP - 427

JO - OMICS A Journal of Integrative Biology

JF - OMICS A Journal of Integrative Biology

SN - 1557-8100

IS - 3

ER -